Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05388006
Title Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.